학술논문
A phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors.
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2/1/2023 Supplement 1, Vol. 41, pTPS816-TPS816, 1p
Subject
Language
ISSN
0732183X